Corneal Health Solutions

Get There in Time

We’re transforming the standard of care for patients with progressive keratoconus and other corneal ectatic conditions through our commitment to addressing important unmet clinical needs in corneal health.

With inspired innovation, a customer-centric focus, and prolific market access capabilities, we are in the constant pursuit of developing proven solutions in corneal health that empower eye care professionals to deliver optimal care for patients

Contact Sales Rep

Corneal Health Therapies

iLink® Corneal Cross-Linking

iLink® is the only FDA-approved corneal cross-linking procedure proven safe & effective to slow or halt progressive keratoconus.

View Therapy

What are the signs and symptoms of progressive keratoconus, and how can corneal cross-linking help?

Learn More

Resources for Your Practice

Our Comprehensive Support.
Your Uncompromising Patient Care.

Integrating iLink® into your practice helps you expand care, and provide a wider range of benefits to many of your patients. As a trusted industry leader, we have the experience, tools, and training to make integration easy.

Physician
Resources

Highly-personalized
practice resources.

View Resources

Clinical
Data

Outcomes for trials conducted on
the iLink® procedure

View Clinical Data

Market Access Support

Looking for
Insurance
Reimbursement
Information?

Every patient deserves access to procedures that can help preserve their vision. iLink® corneal cross-linking helps patients avoid sight-threatening disease progression. That’s why GPS (Glaukos Patient Services) provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Learn More

Explore Patient Resources for Keratoconus Treatment Options

View Patient Website

Find a Physician Performing the iLink® Corneal Cross-Linking Procedure

Go to Physician Locator

Contact Us Today
to Integrate the iLink®
Procedure Into Your
Practice

Explore additional information about iLink® in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.

Request
More Info

"*" indicates required fields

Address*
Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Reference

1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022

View Prescribing Information

Please Select Your Country

Continue